The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
MCF10DCIS.com Xenograft Model of Human Comedo Ductal Carcinoma In Situ
Open accessAbstract
Ductal carcinoma in situ (DCIS) is becoming increasingly common, accounting for 25%–30% of newly diagnosed cases of breast cancer (1). The comedo type represents about 40% of the cases and carries the worst prognosis (2). The subsequent incidence of recurrence in patients presenting previously with comedo DCIS was 20% compared with 5% for noncomedo DCIS in one study (3). National Surgical Adjuvant Breast and Bowel Project Protocol B-17 reported a 40% incidence of ipsilateral breast cancer after lumpectomy of comedo DCIS and found that comedo necrosis is the only important predictor for recurrence after lumpectomy (4). A recurring theme in the National Institutes of Health Breast Cancer Progress Review Group report (http://osp.nci.nih.gov/PRGReports/BPRGReport/bprgtableofcontents.htm) is the need for xenograft models of early human breast disease such as DCIS. The MCF10 model includes normal immortalized breast epithelial cells (MCF10A), premalignant variants (MCF10AT lines) that form simple ducts in xenografts, and malignant variants (MCF10CA lines) (5–7). The clonal cell line MCF10DCIS. com was cloned from a cell culture initiated from a xenograft lesion obtained after two successive trocar passages of a lesion formed by premalignant MCF10AT cells. Injection of MCF10DCIS.com within 22 passages resulted in rapidly growing lesions that are predominantly comedo DCIS. The tumor mass is composed of tightly packed tubular structures, many with central necrosis (Fig. 1). Silver staining reveals distinct intact basement membranes surrounding each ductular structure and emphasizes the necrotic centers (Fig. 1, A). The central necrosis is coagulative and often infiltrated with neutrophils. Mitotic figures are frequent and epithelial cells have moderate amounts of foamy cytoplasm (Fig. 1, B). The nuclei are large and vesicular with large nucleoli. In some areas, the cytoplasm is clear and the cell boundaries are well defined. A distinct myoepithelial layer exists along the basement membrane. A desmoplastic response is evident around some ducts. Although early (3-week) lesions are predominantly DCIS, invasive areas develop and may account for half of the older (9-week) lesions. Further evidence of the progressive potential of the line is that late-passage cells (passage 37) have a more extensive invasive component. These results are reproducible with both the early-passage MCF10DCIS. com and the late-passage progeny. Lesions that are composed predominantly of DCIS have been obtained in all lesions formed in mice in four independent trials (two/two lesions from passage 12; six/six from passage 17; six/six from passage 18; and two/two from passage 22). Similarly, late-passage cells formed mixed lesions with major invasive components in three independent experiments. In summary, we have obtained a human cell line that forms DCIS when xenografted into immunodeficient mice. This property should render it very useful for the testing of chemopreventive agents, for the screening of cancer-causing agents, and for genetic analyses. The fact that this cell line is a member of the MCF10 panel of cell lines, derived from a single patient, representing sequential stages of progression as shown by xenograft lesion formed, makes it all the more valuable for the analysis of genetic progression in human breast disease. Histologic appearance of MCF10DCIS.com xenografts in severe combined immunodeficient mice. A) Silver stain demonstrating basement membrane surrounding duct and comedo necrosis (N) within ducts in a day 36 xenograft of passage 17 MCF10DCIS.com (scale bar = 80 μm). B) Day 22 xenograft of passage 22 MCF10DCIS.com (hematoxylin–eosin; scale bar = 20 μm).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, E. R., Dignam, J., Tan-Chiu, E., Costantino, J., Fisher, B., Paik, S., Wolmark, N., & for the National Surgical Adjuvant Breast Bowel Project (NSABP) Collaborating Investigators (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990801)86:3<429::aid-cncr11>3.0.co;2-y · Cited by 500
MCF10AT: a model for the evolution of cancer from proliferative breast disease.
Dawson, P. J., Wolman, S. R., Tait, L. R., Heppner, G. H., & Miller, F. R. (1996) · Europe PMC (PubMed Central) · Cited by 314
Self-citationXenograft Model of Progressive Human Proliferative Breast Disease
Miller, F. R., Soule, H. D., Tait, L., Pauley, R. J., Wolman, S. R., Dawson, P. J., & Heppner, G. H. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.21.1725 · Cited by 206
Self-citation
Cited by
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis
Zhou, W., Fong, M. Y., Min, Y., Somlo, G., Liu, L., Palomares, M. R., Yu, Y., Chow, A., O’Connor, S. T. F., Chin, A. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.007 · Cited by 1,476
Wei, S. C., Fattet, L., Tsai, J. H., Guo, Y., Pai, V. H., Majeski, H. E., Chen, A. C., Sah, R. L., Taylor, S. S., Engler, A. J., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3157 · Cited by 948
Regulation of In Situ to Invasive Breast Carcinoma Transition
Hu, M., Yao, J., Carroll, D. K., Weremowicz, S., Chen, H., Carrasco, D., Richardson, A., Violette, S., Nikolskaya, T., Nikolsky, Y., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.007 · Cited by 502
Tumours with PI3K activation are resistant to dietary restriction
Kalaany, N. Y., & Sabatini, D. M. (2009) · Nature · doi:10.1038/nature07782 · Cited by 468
Metadata
- Authors
- Miller, F. R., Santner, S. J., Tait, L., & Dawson, P. J.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-07-19
- Volume
- 92
- Issue
- 14
- Pages
- 1185a-1186
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2051692904
- Cited by
- 342
- References
- 3
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MCF10DCIS.com Xenograft Model of Human Comedo Ductal Carcinoma In Situ. https://app.cochat.ai/papers/10.1093/jnci/92.14.1185a
- The paper
- Miller, F. R., Santner, S. J., Tait, L., & Dawson, P. J. (2000). MCF10DCIS.com Xenograft Model of Human Comedo Ductal Carcinoma In Situ. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/92.14.1185a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.